The license for ParActin 50% total andrographolides (comprised of andrographolide, 14-deoxyandrographolide, neoandrographolide) specifies that 1 capsule of 150 mg twice daily “Helps to relieve joint health associated with osteoarthritis of the knee.”
“Canadian consumers will now be able to purchase ParActin-containing supplements clearly for joint health, and can be comfortable discussing usage with their osteopaths, general practitioners and naturopaths," Eng said in the press release, noting that while this claim can only be used by marketers in Canada, it shows the trust by a national regulatory agency in the sufficiency of research demonstrating the efficacy of a relatively small dose of ParActin for joint support.
The two published human clinical trials on ParActin:
- Hancke et al. Clinical Rheumatology, 2009 DOI 10.1007/s10067-009-1180-5
- Juan L. Hancke, Shalini Srivastav, Dante D. Cáceres, Rafael A. Burgos “A double-blind, randomized, placebo-controlled study to assess the efficacy of Andrographis paniculata standardized extract (ParActin®) on pain reduction in subjects with knee osteoarthritis. May 2019 https://onlinelibrary.wiley.com/doi/abs/10.1002/ptr.6339